NASAL ALLERGY AND CONGESTION RELIEF 50 MCG
MOMETASONE FUROATE : 50 MCG · DIN 02451905 · APOTEX INC
Health Canada status: APPROVED
What is NASAL ALLERGY AND CONGESTION RELIEF?
NASAL ALLERGY AND CONGESTION RELIEF 50 MCG contains MOMETASONE FUROATE : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02451905, held by APOTEX INC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as approved, status dated 11-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02451905 |
|---|---|
| Brand name | NASAL ALLERGY AND CONGESTION RELIEF |
| Generic / active ingredient | MOMETASONE FUROATE : 50 MCG |
| Manufacturer | APOTEX INC |
| Strength | 50 MCG |
| Dosage form | SPRAY, METERED DOSE |
| Route of administration | NASAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R01AD09 MOMETASONE |
| AHFS class | 52:08.08 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 11-Feb-2016 |
What can be used instead?
Other Canadian products sharing ATC code R01AD09 MOMETASONE. 6 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02403587 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANIS HEALTH INC | MARKETED | DIN 02519127 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02551756 |
| NASONEX | 50 MCG | SPRAY, METERED DOSE | ORGANON CANADA INC. | MARKETED | DIN 02238465 |
| SANDOZ MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02449811 |
| TEVA-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | TEVA CANADA LIMITED | MARKETED | DIN 02475863 |
| MOSASPRAY | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02455870 |
| NASONEX ALLERGY AND CONGESTION | 50 MCG | SPRAY, METERED DOSE | MERCK CANADA INC | CANCELLED PRE MARKET | DIN 02410524 |
Who else supplies MOMETASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOMETASONE appears in 2383 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of NASAL ALLERGY AND CONGESTION RELIEF
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.